• 한국생물공학회:학술대회논문집
• /
• 한국생물공학회 2003년도 생물공학의 동향(XII)
• /
• pp.533-538
• /
• 2003

To establish an effective and reliable technique of mutation by protoplast regeneration in doxorubicin overproducing industrial strain, it is essential to optimize the conditions for protoplast regeneration. $CaCO_3$ as buffer, the negative effect of glucose was still evident without significant changes in pH, ruling out acidity as responsible for the suppression of anthracycline production and suggesting a direct effect of glucose on antibiotic biosynthesis. Production of doxorubicin was improved in doxorubicin overproducing industrial strain (BR-Dox) when protoplast regenerated. BR-Dox4 and BR-Dox6 of BR-Dox derivatives improved doxorubicin production by 25.2 % and 12.2 %, respectively.

• Advances in Traditional Medicine
• /
• 제5권2호
• /
• pp.137-143
• /
• 2005

Doxorubicin induces oxidative stress leading to cardiotoxicity causing electrocardiogram abnormalities and increases in biomarkers associated with toxicity. Green tea extract (GTE) is reported to possess antioxidant activity mainly via its polyphenolic constituent, catechins. This study was intended to determine the effect of various doses of GTE (25, 50 and 100 mg/kg/day p.o. for 30 days) on doxorubicin-induced electrocardiographic and biochemical changes in rat heart. The latter included lactate dehydrogenase, creatine kinase, and glutamic oxaloacetate transaminase in serum and superoxide dismutase, catalase, and reduced glutathione, as well as membrane bound enzymes like $Na^+K^+ATPase,\;Ca^{2+}ATPase,\;Mg^{2+}ATPase$ and decreased lipid peroxidation in heart tissue Results demonstrated that rats which received GTE were less susceptible to such changes indicating protection afforded by GTE.

• 약학회지
• /
• 제32권4호
• /
• pp.230-233
• /
• 1988

This study was undertaken to elucidate the role of L-carnitine on cardiotoxicity induced by doxorubicin in mice. We designed to investigate both lipoperoxidation and histopathology in experimental group. The results obtained from prior with concurrent treatment of L-carnitine showed as follows; 1) Combination of L-carnitine showed significant inhibition of lipoperoxide in liver than heart. 2) By means of electron microscopy, we obtained histological evidence that doxorubicin-induced cardiomyopathy, is prevented by L-carnitine.

• Bulletin of the Korean Chemical Society
• /
• 제22권6호
• /
• pp.581-586
• /
• 2001

The potential anticancer agents, new anthracycline analogues (2-9) have been synthesized from the glycosides daunomycin (1a) and doxorubicin (1b). Compounds 2 and 6 were prepared by nucleophilic displacement esterification of a 14-bromodauomycin(1c) with sodium or potassium salts of butyric and all trans retinoic acid, respectively. Compounds 3 and 7 were obtained from daunomycin (1a) by direct amidation with a butyric and all trans retinoic acid in the presence of EDCI and PP, respectively. Compounds 4 and 8 were obtained from doxorubicin (1b) by reaction with the corresponding acids in the same manner. Compounds 5 and 9 were prepared from doxorubicin (1b) by acylation with two equivalents of the corresponding acids under the same reaction conditions.

• 대한한의학방제학회지
• /
• 제12권2호
• /
• pp.119-137
• /
• 2004

In order to evaluate the anti-tumor and synergic effect of Soonkiwhajungtang with doxorubicin, the inhibitory concentration(IC), $IC_{50}\;and\;IC_{90}$ of single use of doxorubicin and Soonkiwhajungtang with their concomitant treatment against Colon-26(Murine Rectum Carcinoma) was observed using MTT(Microculture Tetrazolium test) assay. In addition, their anti-tumor effects were also observed in the xenograft nude mice models agianst to Colon-26 cell lines. Soonkiwhajungtang has only mimic direct anti-tumor effect against to Colon-26 cell lines but they were decreased general depressed signs induced by implantation of tumor cell lines and increased the total WBC and lymphocyte numbers. So, it is considered or expected that Soonkiwhajungtang extracts were reduced the critical toxicity of doxorubicin and shows favorable synergic effect with doxorubidn and Soonkiwhajungtang extracts.

• 대한암한의학회지
• /
• 제23권1호
• /
• pp.33-43
• /
• 2018

Objectives: To observe the mitigating effects of a Traditional Korean Medicine(TKM) treatment program especially including pharmacopuncture, with Cyclophosphamide and doxorubicin chemotherapy on a both sides breast cancer patient. Methods: AA 74 year-old female patient diagnosed with both sides breast cancer (Right) pT1bpN0M0, (Left) pT1cpN1Mx was admitted to hospital of Dong-eui university in May of 2017. She received Cyclophosphamide and Doxorubicin from May $31^{st}$ to August $2^{nd}$, 2017 followed by TKM treatment consisting of herbal medicine, acupuncture, moxibustion and pharmacopuncture (Trionycis Carapax, Non-toxic Bee Venom, and Cultivated Wild Ginseng Extract) for a period of almost 4 months, from May $13^{th}$ to August $19^{th}$, 2017. Symptoms were evaluated by the grade of chief complaints refer to Common Terminology Criteria for Adverse Events (CTCAE) and Eastern Cooperative Oncology Group (ECOG). Results: TKM including pharmacopuncture alleviated chemotherapy-induced nausea, fatigue, joint pain, diarrhea, insomnia. Conclusions: This case study potentiates TKM with pharmacopuncture's significant efficacy in aiding breast cancer patients suffering from Cyclophosphamide plus Doxorubicin induced adverse effects. Further research should take place for clear understanding of the exact amount of dosage and safety. Moreover it must be accompanied by long-term follow up researches.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권6호
• /
• pp.2391-2395
• /
• 2015

Objective: The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma. Materials and Methods: Eighteen recurrent or refractory osteosarcoma patients who were treated with continuous-infusion ifosfamide and doxorubicin combination between May 1999 and April 2011 were included in the analysis. Ifosfamide at $12g/m^2$ was administered by intravenous continuous infusion over 3 days, and doxorubicin $60mg/m^2$ was administered as an intravenous bolus injection on day 1. The combination therapy was repeated every 3 weeks. Treatment was continued until evidence of disease progression or unacceptable toxicity. Results: The patients (ages 7-53 years) received a total of 42 cycles of chemotherapy (median: 2 courses; range: 2-5 courses). The overall response rate was 0% and the disease control rate was 22.3%, with four patients having stable disease. The median time to progression and overall survival time were 2 months (range: 2-5 months) and 9 months (range: 3-29 months), respectively. Major severe toxicities were leucopenia 7 (38.9%), nausea and vomiting 3 (16.7%) and alopecia 9 (50%). There were no treatment-related deaths. Conclusions: In our experience, continuous-infusion ifosfamide and doxorubicin combination therapy at this dosage and schedule was found to be well tolerated and moderate effective, which could be considered as salvage therapy for patients with recurrent or refractory osteosarcoma. Further assessment is necessary to confirm the safety and efficacy of this treatment.

• Safety and Health at Work
• /
• 제14권2호
• /
• pp.237-242
• /
• 2023

Background: This study evaluated occupational exposure levels of doxorubicin in healthcare workers performing rotational intraperitoneal pressurized aerosol chemotherapy (PIPAC) procedures. Methods: All samples were collected during PIPAC procedures applying doxorubicin to an experimental animal model (pigs). All procedures were applied to seven pigs, each for approximately 44 min. Surface samples (n = 51) were obtained from substances contaminating the PIPAC devices, surrounding objects, and protective equipment. Airborne samples were also collected around the operating table (n = 39). All samples were analyzed using ultra-high performance liquid chromatography-mass spectrometry. Results: Among the surface samples, doxorubicin was detected in only five samples (9.8%) that were directly exposed to antineoplastic drug aerosols in the abdominal cavity originating from PIPAC devices. The telescopes showed concentrations of 0.48-5.44 ng/cm² and the trocar showed 0.98 ng/cm² in the region where the spraying nozzles were inserted. The syringe line connector showed a maximum concentration of 181.07 ng/cm², following a leakage. Contamination was not detected on the surgeons' gloves or shoes. Objects surrounding the operating table, including tables, operating lights, entrance doors, and trocar holders, were found to be uncontaminated. All air samples collected at locations where healthcare workers performed procedures were found to be uncontaminated. Conclusions: Most air and surface samples were uncontaminated or showed very low doxorubicin concentrations during PIPAC procedures. However, there remains a potential for leakage, in which case dermal exposure may occur. Safety protocols related to leakage accidents, selection of appropriate protective equipment, and the use of disposable devices are necessary to prevent occupational exposure.

• 분석과학
• /
• 제17권6호
• /
• pp.470-475
• /
• 2004

박막흐름전지 (TLFC)의 작업전극인 유리질 탄소전극 (GCE; $A=0.208cm^2$) 표면에 $5{\mu}L$의 HgO 피복용액 (0.5% HgO + 0.25% polystyrene/cyclohexanone)을 피복시키고 pH 4.5 acetate buffer를 흘려주면서 -0.40 V에서 300초간 전해시켰을 때 doxorubicin의 전기환원에 대하여 최대의 감도를 나타내는 수은피막 박막흐름전지 (MFTLFC)를 제작할 수 있었다. MFTLFC에서 doxorubicin은 Ag/AgCl (3 M NaCl)에 대하여 -0.53 V에 이르러 확산전류 (Id)값을 주었으며 수식하지 않은 GCE를 사용한 박막흐름전지 (TLFC)에서 보다 1.7배 더 큰 Id를 나타내었다. 봉우리 면적 (전하)을 doxorubicin과 daunorubicin 표준용액 농도에 대하여 도시한 결과, $1.0{\times}10^{-8}M{\sim}1.0{\times}10^{-6}M$ 농도범위에서 검량인자는 각각 $1.12{\times}10^8{\mu}C/M$ (상관계수: 0.969)과 $0.98{\times}10^8{\mu}C/M$ (상관계수: 0.999)이었다.

• Archives of Pharmacal Research
• /
• 제22권4호
• /
• pp.380-383
• /
• 1999

Five 1-azzanthraquinone-3-carboxamides were synthesized and evaluated in vitro cytotoxicity against four human cancer cell lines. The most active compound, 7b, exhibited cytotoxic activity comparable to doxorubicin.